Your browser doesn't support javascript.
loading
PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of Vildagliptin in the early renal post-transplant period) study: study protocol for a randomized controlled study.
Gaiffe, E; Crepin, T; Bamoulid, J; Courivaud, C; Büchler, M; Cassuto, E; Albano, L; Chemouny, J M; Choukroun, G; Hazzan, M; Kessler, L; Legendre, C; Le Meur, Y; Ouali, N; Thierry, A; Anota, A; Nerich, V; Limat, S; Bonnetain, F; Vernerey, D; Ducloux, D.
Afiliação
  • Gaiffe E; CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, F-25000, Besançon, France.
  • Crepin T; INSERM, UMR1098, EFS-BFC, University Burgundy Franche-Comte, LabEx LipSTIC, FHU INCREASE, F-25000, Besançon, France.
  • Bamoulid J; CHU Besançon, CIC Biothérapie, INSERM CIC1431, F-25000, Besançon, France.
  • Courivaud C; CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, F-25000, Besançon, France.
  • Büchler M; INSERM, UMR1098, EFS-BFC, University Burgundy Franche-Comte, LabEx LipSTIC, FHU INCREASE, F-25000, Besançon, France.
  • Cassuto E; CHU Besançon, CIC Biothérapie, INSERM CIC1431, F-25000, Besançon, France.
  • Albano L; CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, F-25000, Besançon, France.
  • Chemouny JM; INSERM, UMR1098, EFS-BFC, University Burgundy Franche-Comte, LabEx LipSTIC, FHU INCREASE, F-25000, Besançon, France.
  • Choukroun G; CHU Besançon, CIC Biothérapie, INSERM CIC1431, F-25000, Besançon, France.
  • Hazzan M; CHU Besançon, Department of Nephrology, Dialysis, and Renal Transplantation, Federation Hospitalo-Universitaire INCREASE, F-25000, Besançon, France.
  • Kessler L; INSERM, UMR1098, EFS-BFC, University Burgundy Franche-Comte, LabEx LipSTIC, FHU INCREASE, F-25000, Besançon, France.
  • Legendre C; CHU Besançon, CIC Biothérapie, INSERM CIC1431, F-25000, Besançon, France.
  • Le Meur Y; CHU Bretonneau, Department of Nephrology and Clinical Immunology, EA 4245 Transplantation, Immunology, Inflammation, F-37044, Tours, France.
  • Ouali N; Pasteur hospital, L'Archet hospital group, Department of Nephrology, Dialysis, and Renal Transplantation, F-06000, Nice, France.
  • Thierry A; Pasteur hospital, L'Archet hospital group, Department of Nephrology, Dialysis, and Renal Transplantation, F-06000, Nice, France.
  • Anota A; CHU de Rennes, Department of Nephrology, F-35033, Rennes, France.
  • Nerich V; CHU Amiens, Department of Nephrology, Dialysis, and Renal Transplantation, F-80054, Amiens, France.
  • Limat S; CHU de Lille, Nephrology department, University of Lille UMR 995, F-59000, Lille, France.
  • Bonnetain F; CHU Strasbourg, Department of Endocrinology, Diabetes and Nutrition, F-67000, Strasbourg, France.
  • Vernerey D; Necker hospital, Department of Nephrology, Dialysis, and Renal Transplantation, F-75743, Paris, France.
  • Ducloux D; Department of Nephrology, CHU de Brest, UMR1227, Université de Brest, Inserm, F-29609, Brest, France.
Trials ; 20(1): 375, 2019 Jun 21.
Article em En | MEDLINE | ID: mdl-31227028

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Transplante de Rim / Diabetes Mellitus / Vildagliptina Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ensaios Clínicos Controlados Aleatórios como Assunto / Transplante de Rim / Diabetes Mellitus / Vildagliptina Tipo de estudo: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Humans / Middle aged Idioma: En Ano de publicação: 2019 Tipo de documento: Article